co nyse qqq
lilli recent launch drug set firm industry-
lead growth near term
updat forecast estim dec
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research dec
estim dec
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
innov cultur strong financi commit
develop next gener drug set compani apart
peer fuel long-term growth follow steep
patent cliff lilli growth prospect improv
compani launch sever new blockbust patent loss
fade
lilli intern pipelin well posit mitig patent
loss next decad compani tend spend
sale financ develop effort new drug
much higher midteen industri averag robust
pipelin result lilli strong commit research
believ recent approv diabet drug trulic tradjenta
jardianc immunolog drug taltz olumi hold
highest sale potenti lilli new drug also sever lilli
cancer drug cyramza verzenio develop
blockbust addit clinic data hold
lilli strong entrench insulin product also help
compani deal patent loss unlik tradit drug
lilli insulin drug hard copi gener creat
barrier entri noninsulin produc larg
up-front invest need creat scale effici
lilli longer-act biosimilar insulin help compani
secur market share
compani take hard look bottom line
combin cost save expect top-lin growth lilli
aim reach oper margin believ
achiev lilli expect increas gross margin
product initi greater capac util overal
view strong traction recent launch high-margin drug
immunolog oncolog support overal profit gain
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta verzenio cancer forteo osteoporosi jardianc trulic
humalog humulin diabet taltz olumi immunolog
ciali erectil dysfunct
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
slightli reduc fair valu estim
per share base incorpor higher
trend industri believ lilli like face
elev legal cost defend product portfolio
howev still view lilli strong outlook
split anim health busi continu strong
gain sever new product includ trulic
compani abil expand oper margin look
promis divest anim health busi
aggreg compani look well-posit drive
top-lin growth project annual sale increas
next decad result new drug launch
offset patent loss particular outlook
immunolog drug taltz olumi look strong
clinic data support drug becom leader
immunolog outsid immunolog expect diabet
drug jardianc trulic along cancer drug
cyramza becom increasingli import driver cash
flow particular jardianc look pois hit peak sale
project billion base strong cardiovascular
data anoth import point drive valuat cost
control increasingli think lilli abl meet
estim achiev oper margin
close improv
outcom oper cost control depend new
revenu associ success recent launch
drug pipelin expect lilli reach goal
addit estim weight cost capit lilli
line compani peer group
larg base low volatil cash flow
divers inelast product portfolio rate lilli
uncertainti medium larg line
pharma peer group howev lilli slightli
uncertainti partli high product concentr
risk surround compani pipelin recent
launch drug repres one fifth sale
end next year scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show moder
varianc henc medium uncertainti rate factor
affect scenario analysi includ degre
success brand drug pipelin magnitud
market pressur current market drug larg
amount valuat driven pipelin success
new drug launch clinic trial amplifi
impact lilli valuat lastli ad
potenti healthcar polici reform relat drug
price bear case creat addit
pressur bear-cas valuat
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
mean compani top drug repres moder
amount total sale largest drug trulic
repres total sale set manag
cash flow declin new product mitig gener
competit also lilli oper structur allow
cost-cut patent loss reduc margin
pressur lost high-margin drug sale overal lilli
establish product line creat enorm cash flow
need fund averag million develop
cost per new drug addit compani power
distribut network set compani strong partner
smaller drug compani lack lilli resourc lilli
entrench insulin franchis creat ad layer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
macro environ lilli sever headwind
make solid strateg move address challeng
neg side risk-sensit food drug
administr gener approv safe drug
drug high-ne area cancer also
managed-car organ pharmaci benefit
manag consolid past decad
use grow size demand lower drug price
reduc coverag less innov drug forc drug
firm push true innov reduc power
lilli distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov lilli sever headwind pipelin
hold sever biolog drug hold much stronger
competit advantag tradit small molecul
compani pipelin focus
innov treatment area unmet medic need
payer coverag price power remain strong
outsid pipelin compani strong insulin franchis
sale carri extra protect award
biolog economi scale need produc
rel lower-pr drug
competit advantag
competit seem mani year away due complex
gain gener approv insulin high cost
build need economi scale insulin product
hurdl tradit small molecul biosimilar
gain market share follow eventu patent expir
given deceler patent loss strong pipelin
believ moat trend stabl next five
year compani key patent loss includ erectil
dysfunct drug ciali osteoporosi drug forteo
potenti cancer drug alimta patent loss
next five year affect close total sale
compani strong pipelin combin stabl current
market drug lead annual revenu
growth period pipelin side
expect billion peak annual sale psoriasi
drug taltz rheumatoid arthriti drug olumi also
strong cardiovascular data lilli diabet drug trulic
drive drug peak annual sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
olilli launch new immunolog drug taltz
olumi offer better efficaci stronger
safeti profil tnf drug like set
olilli recent divestitur anim healthcar group
enabl firm focu higher-margin
olilli increas focu develop drug
unmet medic indic neurolog oncolog
strategi improv success rate
food drug administr drive strong price
olilli lag immuno-oncolog market may
creat competit headwind older cancer
osever lilli recent launch diabet drug
year behind competit launch
lack differenti could slow market share
oth alimta composit matter patent expir
could bring gener market
weaker patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
strong cash flow deriv stabl diversifi
product portfolio remain solid financi foot
expect compani debt/ebitda level fall
close time close time
also expect debt/capit ratio fall close
cash flow accru
year strong growth prospect expect
lilli need make major acquisit drive
growth nevertheless expect tuck-in acquisit
augment growth compani next decad
adjust free
gener
gener revolv adjust
commit
gener
manufactur brand-nam drugmak also
govern managed-car organ continu
consolid purchas power exert price
challeng liabil lawsuit patent risk
cancer drug alimta sale elev
patent strong composit matter patent
increas likelihood earlier-than-expect gener
competit also strong data novo new drug
like weigh growth prospect trulic overal
rate firm uncertainti medium
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
view lilli stewardship rel standard
mix track record capit alloc believ
lilli use billion acquir imclon
like gener good return partnership
boehring ingelheim greatli improv strateg outlook
compani verdict still regard lilli
decis spend industry-lead amount capit
percentag sale research develop
pipelin look strong phase data need
determin return invest lilli
purchas price novarti anim healthcar busi
billion appear high
entrench anim health increas lilli competit
advantag well-posit industri spin-off
busi like benefit novarti asset
januari dave rick took helm
ceo follow smooth transit previou ceo
john lechleit retir rick bring strong experi
previous serv presid lilli biomedicin
group cover alzheim diseas urolog
immunolog musculoskelet diseas pain well
compani global market function rick
experi lilli date back join
compani busi develop associ dont
expect major chang transit senior
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
america corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
post steadi remain posit oct
report third-quart result larg line
expect slow sale growth diabet drug
trulic immunolog drug taltz like weigh
stock price dont expect make major chang
fair valu estim view stock pullback
overdon continu view lilli wide moat
one well-round portfolio current
market drug pipelin drug across stage
launch drug
quarter total sale increas oper
despit major gener pressur erectil dysfunct drug
ciali sever new drug post solid gain sheer
number recent
lead
acceler growth margin expans close
basi point gener pressur annual
remain bullish diabet drug jardianc driven like
indic expans trulic support favor
aid new indic favor head-to-head data
strong overal surviv data migrain drug emgal
enter larg potenti market
gain synergi lilli recent approv acut
migrain drug reyvow despit overal strong
posit current portfolio acknowledg
like slow growth trulic face competit
easier take oral drug rybelsu novo also
taltz face increas competit new psoriasi
beyond current portfolio lilli continu back fill
remain bullish late-stag drug trizepatid
diabet mirikizumab immunolog addit
sever early-stag drug potenti game changer
diseas like alzheim dementia cancer also
carri higher uncertainti success
complet review lilli pipelin current
report moat remain secur innov counter
price gener headwind acceler
help off-set gener ciali pressur jul
expect chang fair valu estim
post second-quart result larg
line expect slightli ahead consensu
project view compani modestli under-valued
long-term margin expans like fulli appreci
market project continu gain specialti
drug immunolog drug taltz olumi cancer
drug verzenio neurosci drug emgal
post excel growth quarter expect
continu margin expans base strong price
power drug expect increas
margin lilli base innov drug help
reinforc wide moat rate
quarter total sale increas oper
gener pressur erectil dysfunct drug ciali
weigh strong growth seen recent
launch specialti drug continu gain diabet
drug trulic expect gener pressur ciali
continu weigh overal growth remaind
year expect growth acceler
base continu new product growth less gener
pressur addit expect continu growth
compani largest drug trulic
project increas competit novo nordisk oral
diabet drug semaglutid slow trulic gain start
howev recent launch drug pois
keep lilli total sale growth high end industri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
lilli continu make excel progress pipelin
remain bullish new indic taltz
radiograph nonradiograph axial spondylarthr
expect approv migrain drug lasmiditan
diabet drug tirzepatid also lilli
seek approv pain drug tanezumab remain skeptic
drug potenti base mix long-term safeti
complet review lilli pipelin current
report moat remain secur innov counter
price gener headwind acceler
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
co nyse qqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
